HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
HCW Biologics Inc. announced receipt of a U.S. patent allowance for the use of their lead IL-2-based immunotherapeutic HCW9302 as a treatment for alopecia areata. The Phase 1 dose-escalation clinical study is progressing on schedule with encouraging preliminary responses and no dose-limiting toxicities. The company's intellectual property estate ha…